T-cell lymphoma

6 trials 5 recruiting MedDRA PT
6 Registered trials
5 Recruiting
6 Unique sponsors
7 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 5
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 4 substances
CDK inhibitor 1 substance
Alkylating agent 1 substance
Antimetabolite 1 substance
Phase II: 1 Phase I/II: 3 Phase I: 1 Phase I (First in Human): 1

Filter these 6 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 6 trials

Phase II

1 trial
  • Aalborg University Hospital Academic
    IMP not specified
    2025-521205-41-00 1 country 2026 n=74
    Recruiting

Phase I/II

3 trials
  • Cyclacel Limited Commercial
    FADRACICLIB
    2024-516289-12-00 1 country 2022 n=30
    Ended
  • Taiho Oncology Inc. Commercial
    DECITABINE, CEDAZURIDINE; TOLINAPANT LACTATE
    2022-500391-62-00 5 countries 2023 n=77
    Recruiting
  • Xenothera Commercial
    ANTI-T LYMPHOCYTE IMMUNOGLOBULIN FOR HUMAN USE, PIG
    2023-509648-88-00 2 countries 2024 n=34 Orphan
    Recruiting

Phase I

1 trial
  • Step Pharma Academic
    IMP not specified
    2022-502299-21-00 1 country 2023 n=85
    Recruiting

Phase I (First in Human)

1 trial
  • Ospedale Pediatrico Bambino Gesu Academic
    CD7-CART01; CYCLOPHOSPHAMIDE; FLUDARABINE PHOSPHATE
    2023-508355-39-00 1 country 2024 n=26
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Cyclacel Limited Commercial 1 Phase I/II 0
Taiho Oncology Inc. Commercial 1 Phase I/II 1
Xenothera Commercial 1 Phase I/II 1
Step Pharma Academic 1 Phase I 1
Aalborg University Hospital Academic 1 Phase II 1
Ospedale Pediatrico Bambino Gesu Academic 1 Phase I (First in Human) 1
New trials by year
2022
1
2023
2
2024
2
2026
1
← All indication landscapes